GlassScriptPhysician profile
Sima Amin
NPI 1467912006
$2,477.74
in general payments reported to CMS, 2019-2025
16 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $52.98 · 2022: $228 · 2023: $204 · 2024: $610 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,102 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.50 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $463.60 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $416.39 | 2024-2025 | |
| Abbvie INC. | $229.27 | 2023-2025 | Rinvoq |
| Genzyme Corporation | $216.74 | 2025 | |
| Janssen Biotech, INC. | $197.51 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $177.34 | 2025 | Ebglyss, Taltz |
| Organon LLC | $150.00 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2023 | Libtayo |
| Galderma Laboratories, L.P. | $100.25 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $99.06 | 2022 | |
| Leo Pharma INC. | $68.12 | 2025 | Adbry |
| Dermavant Sciences, INC. | $56.17 | 2024 | Vtama |
| Vyne Pharmaceuticals INC. | $52.98 | 2020 | |
| Amgen INC. | $46.81 | 2025 | Otezla |
| Incyte Corporation | $43.31 | 2024-2025 | Opzelura |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $38.35 | 2025 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sima Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.